lunedì, 14 settembre 2026

Notizie AIOM – anno XV n. 640

FDA Grants Venetoclax Breakthrough Designation for AML Subpopulation

July 28, 2017 - Venetoclax has received an FDA breakthrough therapy designation for use in combination with low dose cytarabine (LDAC) in treatment-naïve elderly patients with acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy, according to Roche, ...
Leggi tutto

FDA Grants Durvalumab Breakthrough Designation for NSCLC

July 31, 2017 - The FDA has granted durvalumab a breakthrough therapy designation to treat patients with locally-advanced, unresectable non-small cell lung cancer (NSCLC) whose disease has not progressed following platinum-based chemoradiation. AstraZeneca and its global ...
Leggi tutto

FDA Awards Acalabrutinib Priority Review in MCL

August 2, 2017 - The FDA has granted a priority review to a new drug application (NDA) for acalabrutinib for patients with previously-treated mantle cell lymphoma (MCL), according to AstraZeneca, the manufacturer of the highly selective, potent BTK inhibitor. The announcement ...
Leggi tutto

FDA Grants Brentuximab Vedotin Priority Review for CTCL

August 16, 2017 - The FDA has granted a priority review to a supplemental biologics license application (sBLA) for brentuximab vedotin for the treatment of patients with cutaneous T-cell lymphoma (CTCL), according to Seattle Genetics, which codevelops the antibody-drug conjugate ...
Leggi tutto

FDA Approves Olaparib Tablets for Ovarian Cancer

August 17, 2017 - The FDA has approved olaparib tablets as a maintenance therapy for patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy, regardless of BRCA status. ...
Leggi tutto

European Commission Approves Frontline Fulvestrant for ER+ Breast Cancer

July 27, 2017 - The European Commission (EC) has approved the use of fulvestrant to treat estrogen receptor (ER)-positive, locally-advanced or metastatic breast cancer in postmenopausal women not previously treated with endocrine therapy. The EC based its decision on results ...
Leggi tutto

Clinical Significance of Four Molecular Subtypes of Gastric Cancer Identified by The Cancer Genome Atlas Project

The Cancer Genome Atlas (TCGA) project recently uncovered four molecular subtypes of gastric cancer: Epstein-Barr virus (EBV), microsatellite instability (MSI), genomically stable (GS), and chromosomal instability (CIN). However, their clinical significances are currently ...
Leggi tutto

Taxanes in combination with platinum derivatives for the treatment of ovarian cancer during pregnancy: A literature review

Ovarian cancer is one of the most common types of solid carcinoma diagnosed during pregnancy. Taxane plus a platinum derivative is a combination therapy that is predominantly used in the treatment of ovarian cancer in non-pregnant women. Pregnancy adds various complexities ...
Leggi tutto

Social influence on 5-year survival in a longitudinal chemotherapy ward co-presence network

Chemotherapy is often administered in openly designed hospital wards, where the possibility of patient-patient social influence on health exists. Previous research found that social relationships influence cancer patient's health; however, we have yet to understand social ...
Leggi tutto

26 luglio 2017 – Nota Informativa Importante su Bendamustina